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Introduction
Diabetes mellitus is a disorder of metabolism, which is a major public health problem in all parts of the world, and recently the World Health Organization suggested that in all parts of the world almost 3 million deaths annually can be attributed to diabetes. Within 10 years, it is expected that about 333 million people world-wide will su er from diabetes mellitus; with Type 2 Diabetes Mellitus (T2DM) representing about 90-95% of cases diagnosed [1] .
STG is an antidiabetic agent of the Dipeptidyl Peptidase-Iv Inhibitor (DPP-IV) class [2] . It was approved by the Food and Drug Administration (FDA) in October 2006 and produced as a single therapy to treat T2DM by Merck Pharmaceutical Company under the trade name Januvia ® .
ese DPP-IV inhibitors are used as monotherapy, and as add-on therapy in patients with T2DM. e FDA agreed to the sitagliptin/metformin (Janumet TM , Merck & Co.) combination in April 2007 as an assistive treatment in combination with diet and exercise to improve control of blood sugar in adult patients su ering from T2DM [3] [4] [5] . patient discontinued the drugs. At present the mechanism responsible for this adverse e ect is not known, either in terms of the chemical species involved or the physiological process a ected. Understanding the metabolic pathways and formation of reactive metabolites will aid understanding of in the vivo metabolism, likely pharmacokinetics and adverse e ects of this class of medicine [6] . e chemical structure of STG is shown on Figure 1 . In the literature, there are Gas Chromatography-Mass Spectrometry (GC-MS) methods for the determination of STG in biological samples. However, these chromatographic studies require a complicated process to enable identi cation of trace amounts of STG metabolites using drying and then derivatisation by Nmethyltrimethylsilyltri uoroacetamide prior to GC-MS analysis and conversion into its N-TMS amine derivative, and these processes might a ect the stability of some metabolites which are formed in trace amounts or indeed they may simply not be volatile enough for GC-MS analysis [7] . On the other hand, Vincent et al. recently reported the phase I and II metabolism of [ 14 C] STG and six metabolites at trace levels in human plasma, urine and faeces using LC-MS 2 and radiometric detection using the TurboIonSpray interface operated in the positive ion mode. Six phase I and II metabolites of STG were observed in both human urine and faeces and these were shown to be products of hydroxylated, N-sulfated STG and two metabolites formed by oxidative desaturation of the piperazine ring followed by cyclization. It was observed that, in all human subjects, the glucuronides were further transformed and were not detected in faeces samples [8] .
Similar observations were shown in rats and dogs, where, as in humans, approximately 10-16% of the radiolabeled oral dose was recovered in the rat and dog excreta as phase I and II metabolites. All the metabolites observed in human plasma, urine, and faeces were also observed in rat and dog plasma, urine, bile, and faeces, as well as in incubations in vitro with rat, dog, and human liver microsomes. However, metabolism was minimal in all species in vitro and in vivo. Results from in vitro experiments with recombinant P450s and monoclonal anti-P450 antibodies showed that the oxidative metabolite of STG in human liver microsomes is catalysed primarily by CYP3A4 with some minor contribution from CYP2C8 [9] . e authors did not detect any other products arising from Phase II metabolism except the glucuronide and sulfate metabolites.
As knowledge of the ADME processes for reactive metabolites is a prerequisite for their toxicological risk assessment it is prudent to elucidate both the phase I and II metabolic pathways for STG especially in the long term administration for this kind of medication.
is paper seeks to address this de ciency by presenting the elucidation and pro le of both phase I and phase II metabolic events in rat hepatocyte preparations using LC-MS and LC-MS 2 methods.
Experimental

Chemical and reagents
All reagents were of commercial quality (obtained from Sigma Aldrich, Gillingham, UK, Alfa-Aesar, Heysham, UK or Fisher Scienti c, Loughborough, UK) and used without further puri cation. Sitagliptin phosphate (STG) was obtained from Kemprotec Limited, UK. HPLC grade acetonitrile was obtained from Fisher Scienti c, UK, and formic acid (98%) was obtained from BDH (DOREST, UK).
e LC separation was performed using a Exactive Orbitrap ( ermo Fisher Scienti c, Hemel Hempstead, UK), which was operated in the positive mode, A ZIC-HILIC Column 5 um 150 mm × 4.6 mm (HiChrom, Reading, UK), and acquisition was performed using XCalibur so ware. Fragmentation experiments were carried out using LTQ Orbitrap ( ermo Fisher Scienti c, Hemel Hempstead, UK).
Data processing
LC/MS raw les were processed by ermo Sieve so ware which can provide variances in the plots, which were highlighted, and the exact masses of ions yielding the di erence could be detected. e parameters used in this so ware were: time range 4-30 min, mass range 75-800 amu, frame width 0.02 amu and Rt width 2.5 min [10] . It can be shown clearly that this so ware detected a di erence in the intensity peaks of the metabolite ions between STG incubated with hepatocytes for 120 min and STG, incubated with bu er alone, and hepatocytes incubated in the absence of STG a er 120 min.
Biotransformation of STG in Sprague-Dawley rat hepatocytes
All animal procedures adhered to UK Home O ce Guidelines and were carried out under Licence PPL/60/3685. e hepatocytes were prepared from male Sprague-Dawley rats (body weight range: 200 250 g, bred in the University of Strathclyde) by collagenase perfusion of the livers using a modi cation of the method by Moldeus et al. [11, 12] .
e cell viability was con rmed using a Trypan blue exclusion test, and was >80%. STG (100 M, a standard concentration used to screen metabolic pathways) was incubated in 50 mL round-bottomed asks with hepatocytes (2 × 10 6 viable cells mL -1 ) in Krebs-Henseleit (K-H) bu er containing 12.5 mM HEPES (pH 7.4).
e samples were incubated with constant rotation at 37°C under an atmosphere of oxygen: carbon dioxide (95:5) for 120 min. Control incubations of (i) rat hepatocytes (in the absence of STG) and (ii) solutions of (STG) dissolved in K-H bu er (pH7.4) was also carried out. All incubations were carried out in triplicate, using three independent animals. e e ciency of recovery from hepatocyte matrix was determined to be 102.6% ± 20.7% (for STG, n=3, ±SD)
Liquid chromatography-mass spectrometry (LC-MS)
Liquid chromatography-mass spectrometry (LC-MS) data were acquired using an Orbitrap Exactive instrument ( ermo-Fisher Corporation, Hemel Hempstead, UK). Sample analysis was carried out with positive ion ESI detection. e mass scanning range was 75-1200 m/z, while the capillary temperature was 250°C, spray voltage was +4.5 kV and the sheath and auxiliary gas (nitrogen) ow rates were 45 and 15, respectively (units not speci ed by the manufacturer). e LC-MS system (controlled by Xcalibur Ver. 2.0, ermo-Fisher Corporation, Hemel Hempstead, UK) was run in binary gradient mode with an injection volume of 10 µL. Solvent A was aqueous formic acid (0.1% v/v) and solvent B was formic acid (0.1% v/v) in acetonitrile; the ow rate was 0.3 mL min 1 . A ZIC ® -HILIC (150 mm × 4.6 mm i.d., particle size: 5 µm) column tted with a ZIC ® -HILIC guard column (HiChrom Limited, Reading, UK) was used for all analyses.
e gradient programme was as follows: 20% A (0 min) to 50% A (at 12 min), to 50% A (at 26 min), to 80% A (at 28 min), to 80% A (at 36 min), to 20% A (at 37 min) and nally re-equilibration with 20% A to 45 min. LC-MS 2 spectra were obtained by using an LTQ Orbitrap ( ermo-Fisher Corporation, Hemel Hempstead, UK) with the same source, control so ware and chromatographic conditions speci ed above. e selected precursor ions were fragmented with a CID voltage of 40 eV. Data processing was carried out using SIEVE Ver. 
Results and Discussion
Con rmation of Sprague-Dawley rat hepatocyte viability e viability of the freshly isolated hepatocytes was 79.5 ± 4.6%, and exposure to STG had no signi cant e ect on viability compared with cells incubated in K-H bu er alone for up to 2 hrs.
Biotransformation of STG in Sprague-Dawley rat hepatocytes
Using the high resolution mass spectrometer, 11 potential STG metabolites were detected by using SIEVE so ware to compare the control incubation with the hepatocyte incubation containing STG. Only 3.1% ± 0.12% of the parent STG was metabolised by the end of the two hr incubation. Five of the eleven metabolites have been previously identi ed [8] , along with products arising from sulfation, glucuronidation, acetylation, hydroxylation and other pathways [9] .
us it was found that rat hepatocytes catalysed both phase I and phase II metabolism of STG and overall eleven metabolites were putatively identi ed (Table 1) . e elemental composition and retention times of the metabolites are listed in Table 1 .
e mass error (when compared to their theoretical masses) of all the detected metabolites were within ±0.5-1 ppm of their assigned elemental composition (Table 1) , however, the most abundant metabolites a er 30 mins incubation were proposed to be aromatic hydroxylation metabolites (M1 , t R =9.7 min/10.1 min; m/ z=424.12), and desaturated metabolites formed through desaturation of N-C and C-C of the piperazine ring (M2 and M2 respectively, t R =9.7 min, 5.7 min; m/z=406.11). M2 was formed from STG by conversion of a tertiary amide to a quaternary amide via C-N desaturation.
e mass spectral fragmentation pattern (Figure 2 ) shown included fragment ion (m/z 191), and Liu showed similar ndings and obtained the same fragmentation pattern. us M2 was formed through desaturation of C-N and M2 through desaturation C-C of piperazine ring [13] . e levels of most of these metabolites increased further between 30 and 120 min of incubation with a corresponding slight decrease in the level of unmetabolised drug (STG, t R =9.6 min).
In contrast, the level of (M8, t R =6.3 min; m/z=452.12) was similar between 30 min and 120 min and there was an increase in the levels of its corresponding glucuronide (M9, t R =6.5 min; m/z=628.15). e sulfate metabolite (M7, t R =5.12 min; m/z=488.08) could also be clearly observed a er 120 min of incubation and it is considered a stable nontoxic conjugate. In some cases chromatographic information can be used to di erentiate isomeric possibilities.
us metabolite (M1) is proposed to result from hydroxylation on the amine group at the nucleophilic nitrogen forming a hydroxylamine rather than hydroxylation of the aromatic moiety of STG (M1 ), M1 and M1 elute at a di erent retention time (t R =8.25 min, t R =9.7; 10.1 min respectively) on the ZIC ® -HILIC column.
e biotransformation of (STG) observed following its incubation with Sprague-Dawley rat hepatocytes is summarised.
e dynamic range of the instrument was su cient to show both major and minor metabolites. Metabolite M1 and M1 , eluted at 8.25 and 9.7 min, and had a protonated molecular ion [M+H] + at m/z 424.12 which indicates possible hydroxylation at NH 2 (M1) as the largest fragment ion was observed at m/z 391, which can be attributed to the loss of (NH 3 -OH) or loss of 18 D at the aromatic position metabolite (M1 ) to produce fragment ion m/z 406.
Moreover, metabolite M2 and M2 , showed the same protonated molecular ion [M+H] + at m/z 406.1; the molecular ions were 2 Da less than that of STG parent ion, indicating loss of 2 Hydrogen atoms. Due to the lack of reference standards in this study the results could not de ne the exact desaturation positions of M2 and M2 . However, the advantage of the high resolution of mass spectrometry in assignment of the largest fragment at m/z 191 showed the two possible structures of these metabolites as desaturated in C-C and C-N of the piperazine ring (Figure 2 ). In addition, the results of this study indicate that STG is metabolised to an electrophilic form (M2) which is an ionized metabolite, and it may be implicated in adverse e ects of STG, as it is an electrophilic entity capable of irreversible reaction with tissue nucleophiles [14] .
When the primary amine underwent N-oxidation it formed a hydroxylamine. is provides a pathway for metabolic deamination.
us STG is transformed to a hydroxylamine that then underwent dehydration to an imine.
is is subjected to further metabolic oxidation to give an oxime because the imine had hydrogen attached to the nitrogen (M3, m/z 422.10). e carbon of the oxime is electrophilic and water attacks it to form a carbinolhydroxylamine that is then hydrolyzed to form a ketone and hydroxylamine.
us M4 has a protonated molecular ion [M+H] + at m/z 407.09 and was identi ed as a deamination metabolite of STG (Scheme 1) [15] .
Several enzyme systems such as CYP dependent FMOs can catalyze N-Oxidation reactions [16, 17] and this pathway has the potential to lead to metabolites that can damage cells via multiple pathways. Metabolites, such as the N-hydroxyl metabolites, can redox cycle to produce reactive oxygen species and other free radicals, which can damage membranes and lead to oxidative stress [18, 19] .
e primary amine group in STG reacted to form N-glucuronide metabolites (M6, tR=9.3 min; m/z=584.15). e fragmentation pattern showed a mass shi of 176 Da compared with the parent STG, because the amine nucleophilic functional groups react at the acetal carbon of the sugar, inverting the con guration at that site to give an Nglucuronide conjugate. is reaction is catalyzed by UDP-glucuronyl transferase. e hydroxylamine group in M1 also can react to form Oglucuronide metabolites (M5, M5 , t R =6.4, 10 and 11 min; m/ z=600.11). Glucuronide formation is an important step in the elimination of many important exogenous substances from the body; the major glucuronide metabolites observed in the current work were M5 and M6. ere was also a glucuronide as a minor metabolite, an Ncarbamoyl glucuronidation (M9, t R =6.5 min; m/z=628.15).
Karabulut et al. reported that the number of apoptotic cells was the same in the pancreas of healthy and type-2 diabetic rats a er STG administration. Serum glutathione levels did not change in either group. Glutathione conjugated metabolites were not detected in our study [20] , however, the N-oxide metabolite needs further study to fully characterise its pharmacological/toxicological e ects.
De uorination of STG occurred forming (M11, t R =10.4 min; m/ z=422.12) in trace amounts a er two hrs of incubation, presumablyScheme 1: Deamination metabolite of STG.
Metabolic pro ling of Sitagliptin (STG)
Drugs are eliminated from the body by excretion and by transformation to metabolites. ese processes occur simultaneously, but which of these processes predominate varies from one drug to another. As the amount of drug in a system depends on both its rates of absorption and elimination and the amount of a speci c metabolite present also depends on its rate of formation and elimination. e metabolic pro les of STG (pKa=8.78; Log P=1.26) were determined using three separate incubations of the drugs with isolated rat hepatocytes ( Figure 3 ). e relative levels of the detected metabolites of STG indicate that eleven metabolites were identi ed in the freshly isolated cells. e product-ion spectrum of protonation recorded at 40 eV collision energy is shown in Figure 3 and only aromatic hydroxylation STG (M1 , m/z=424.12) was formed in large amounts. In addition, the formation of metabolite (M5 , m/z=600.15) increased a er two hrs incubation period by approximately 100%. In the case of (STG) the histogram indicates that the major metabolites of STG were: (M1 , m/ z=424.11), (M2, m/z=406.10), (M4, m/z=407.09) and (M5 , m/ z=600.15) (Figure 3 ). e amount of (M3) and (M6) increased slowly throughout the two hr incubation period. e majority of Phase II metabolites identi ed in (STG) were found at low levels at 30 min and increased slightly by 120 min.
e N-sulfate metabolite (M7, m/ z=488.08 ) increased slowly though the level was low at 30 as well as 120 min, moreover (M8, m/z=452.12), (M9 m/z=628.15) and (M11 m/ z=422.12) were identi ed at only trace amounts, however, the sensitivity and high resolution of the instrument was su cient to show these minor metabolites.
In a similar case in a healthy male, Herman showed that almost all STG was excreted unchanged in urine and faeces a er oral administration. It was eliminated 87% in urine and 13% in the faeces. Renal clearance involving active tubular secretion was the main elimination pathway [21] . In our study, as can be seen from Table 1 , the results obtained from the preliminary analysis of rat hepatocyte incubations showed both phase I and phase II metabolism of STG. However, the metabolism of STG in liver cells was also minimal. M+H was the major metabolite formed. A considerable amount of literature has been published on STG metabolism. All the metabolites reported in previous studies have been produced in our study when hepatocytes were incubated with STG, except for the glutathione conjugate reported by Beconi [9] which was absent in our study.
e most obvious nding to emerge from the analysis is that total metabolism of STG was only about 3%. It can thus be suggested that the adverse e ects that were reported recently may be caused by the parent drug. is view is supported by Swallow who reported that high metabolic stability and bioavailability of STG of 87% were demonstrated in vivo in healthy volunteers and the author showed that renal clearance of unchanged STG accounted for approximately 70% of the total plasma clearance of STG. erefore, further studies of the adverse e ects of STG which take these variables into account, will need to be undertaken [22, 23] . 
Conclusion
e data presented both con rm and expand upon previously reported observations through the identi cation of all Phase II metabolites, however, no evidence of the formation of ring cyclization a er oxidative desaturation of the piperazine were detected in the current study. STG shows some novel metabolite pathways such as a deaminated metabolite in which the amino group is replaced by oxygen. e key pharmacokinetic parameters for STG reported herein may be of signi cance to medical pharmacologists and can be used to predict both the in vivo metabolism and the likely pharmacokinetic e ects of STG within this class of anti-diabetic substances [24] .
e present study con rms previous ndings of STG metabolism. is study did not con rm formation of a glutathione conjugate metabolite, and for those new metabolites such as diketone metabolite of STG, N-hydroxylation and oxime metabolites, further studies are needed to investigate the pharmacological evaluation.
